Morgan Stanley sees huge upside at AstraZeneca
Morgan Stanley has initiated coverage of pharma giant with an 'overweight' rating, recommending investors to build positions at a "compelling entry point".
The bank hailed AstraZeneca as an "innovation leader", saying that the company has an underappreciated pipeline with exposure to high-value markets across oncology, cardiovascular/renal and next-generation immuno-oncology.
"With pivotal clinical data starting in 2025+, success across these markets, could start to unlock value closer to our bull case valuation, £160/share," Morgan Stanley said. That compares with Tuesday's closing price of 11,624p.
As for the near term, 2025 should be a "catalyst-rich year", delivering double-digit bottom-line growth alongside continued strong product sales momentum, the bank said.
On Morgan Stanley's estimates, the stock trades at 15 times estimated earnings for 2025. While this is a 30% premium to other large-cap pharma peers, it is "justifiable given the superior top-line driven growth outlook [...] and significantly greater pipeline optionality," the bank said.
For now, Morgan Stanley has set a 14,500p target price for the shares, which were down 0.2% at 11,606p by 1054 GMT.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.